Matthew Gline, CEO at Roivant Sciences Ltd. (ROIV), sold 38,552 shares at $4.40 ($170K) on 2022-10-25, disclosed to the SEC on 2022-10-27.
Open-market sale of $170k ROIV by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.40 | 19,276 | $85K | 50.0% |
| 2 | $4.40 | 19,276 | $85K | 50.0% |
| Total | $4.40 avg | 38,552 | $170K | 100% |
| Filing → |
| ROIV | BUY | 2025-09-18 | $50K | — | Filing → |
| ROIV | SELL | 2024-09-24 | $46.8M | — | Filing → |
| ROIV | SELL | 2022-09-27 | $129K | — | Filing → |